Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 57, No 1 (2023)
Review Article
Submitted: 2023-01-17
Accepted: 2023-02-10
Published online: 2023-02-17
View PDF Download PDF file View HTML
Get Citation

Hyperkinetic movement disorders following SARS-CoV-2 infection and vaccination — an update

Filip Przytuła1, Jarosław Sławek12
DOI: 10.5603/PJNNS.a2023.0012
·
Pubmed: 36799521
·
Neurol Neurochir Pol 2023;57(1):63-76.
Affiliations
  1. Neurology&Stroke Department, St. Adalbert Hospital, Gdansk, Poland
  2. Department of Neurological-Psychiatric Nursing, Medical University of Gdansk, Poland

open access

Vol 57, No 1 (2023)
REVIEW ARTICLES — LEADING TOPIC
Submitted: 2023-01-17
Accepted: 2023-02-10
Published online: 2023-02-17

Abstract

The aim of this review was to summarise current knowledge regarding hyperkinetic movement disorders related to SARS-CoV-2 infection and vaccination in terms of phenomenology, epidemiology, pathogenesis and treatment. After a thorough review of the PubMed and Google Scholar databases (2020–2022), we identified myoclonus and ataxia sometimes accompanied by opsoclonus (AMS) as the two most frequent COVID-19 sequelae, with chorea, tremor and dystonia being very rare. The pathogenesis seems to be variable, but in the majority of AMS cases it was autoimmunological, with good response and recovery after corticosteroids or intravenous immunoglobulins infusions. Vaccination may be complicated by hyperkinetic movement disorders (e.g. tremor, dystonia), but this is very rare. Patients with Deep Brain Simulation depletion should not be postponed due to lockdowns as this may result in fatal outcomes.

Abstract

The aim of this review was to summarise current knowledge regarding hyperkinetic movement disorders related to SARS-CoV-2 infection and vaccination in terms of phenomenology, epidemiology, pathogenesis and treatment. After a thorough review of the PubMed and Google Scholar databases (2020–2022), we identified myoclonus and ataxia sometimes accompanied by opsoclonus (AMS) as the two most frequent COVID-19 sequelae, with chorea, tremor and dystonia being very rare. The pathogenesis seems to be variable, but in the majority of AMS cases it was autoimmunological, with good response and recovery after corticosteroids or intravenous immunoglobulins infusions. Vaccination may be complicated by hyperkinetic movement disorders (e.g. tremor, dystonia), but this is very rare. Patients with Deep Brain Simulation depletion should not be postponed due to lockdowns as this may result in fatal outcomes.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

ataxia, myoclonus, opsoclonus, chorea, tremor, dystonia, COVID-19, SARS-CoV-2

About this article
Title

Hyperkinetic movement disorders following SARS-CoV-2 infection and vaccination — an update

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 57, No 1 (2023)

Article type

Review Article

Pages

63-76

Published online

2023-02-17

Page views

3035

Article views/downloads

1141

DOI

10.5603/PJNNS.a2023.0012

Pubmed

36799521

Bibliographic record

Neurol Neurochir Pol 2023;57(1):63-76.

Keywords

ataxia
myoclonus
opsoclonus
chorea
tremor
dystonia
COVID-19
SARS-CoV-2

Authors

Filip Przytuła
Jarosław Sławek

References (88)
  1. Soriano JB, Murthy S, Marshall JC, et al. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022; 22(4): e102–e107.
    CrossRefPubMed
  2. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021; 11(1): 16144.
    CrossRefPubMed
  3. Bratosiewicz-Wąsik J. Neuro-COVID-19: an insidious virus in action. Neurol Neurochir Pol. 2022; 56(1): 48–60.
    CrossRefPubMed
  4. Sutter R, Ristic A, Rüegg S, et al. Myoclonus in the critically ill: Diagnosis, management, and clinical impact. Clin Neurophysiol. 2016; 127(1): 67–80.
    CrossRefPubMed
  5. Brandão PR, Grippe TC, Pereira DA, et al. New-Onset Movement Disorders Associated with COVID-19. Tremor Other Hyperkinet Mov (N Y). 2021; 11: 26.
    CrossRefPubMed
  6. Hirschfeld AS. Autoimmune mediated hyperkinetic movement disorders in SARS-CoV-2 infection - a systematic review. Neurol Neurochir Pol. 2021; 55(6): 549–558.
    CrossRefPubMed
  7. Rábano-Suárez P, Bermejo-Guerrero L, Méndez-Guerrero A, et al. Generalized myoclonus in COVID-19. Neurology. 2020; 95(6): e767–e772.
    CrossRefPubMed
  8. Delorme C, Paccoud O, Kas A, et al. CoCo-Neurosciences study group and COVID SMIT PSL study group. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings. Eur J Neurol. 2020; 27(12): 2651–2657.
    CrossRefPubMed
  9. Wright D, Rowley R, Halks-Wellstead P, et al. Abnormal Saccadic Oscillations Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Encephalopathy and Ataxia. Mov Disord Clin Pract. 2020; 7(8): 980–982.
    CrossRefPubMed
  10. Dijkstra F, Van den Bossche T, Willekens B, et al. Myoclonus and Cerebellar Ataxia Following COVID-19. Mov Disord Clin Pract. 2020; 7(8): 974–976.
    CrossRefPubMed
  11. Schellekens MMI, Bleeker-Rovers CP, Keurlings PAJ, et al. Reversible Myoclonus-Ataxia as a Postinfectious Manifestation of COVID-19. Mov Disord Clin Pract. 2020; 7(8): 977–979.
    CrossRefPubMed
  12. Shah PB, Desai SD. Opsoclonus Myoclonus Ataxia Syndrome in the Setting of COVID-19 Infection. Neurology. 2021; 96(1): 33.
    CrossRefPubMed
  13. Grimaldi S, Lagarde S, Harlé JR, et al. Autoimmune Encephalitis Concomitant with SARS-CoV-2 Infection: Insight from F-FDG PET Imaging and Neuronal Autoantibodies. J Nucl Med. 2020; 61(12): 1726–1729.
    CrossRefPubMed
  14. Salari M, Zaker Harofteh B, Etemadifar M, et al. Movement Disorders Associated with COVID-19. Parkinsons Dis. 2021; 2021: 3227753.
    CrossRefPubMed
  15. Chan JL, Murphy KA, Sarna JR. Myoclonus and cerebellar ataxia associated with COVID-19: a case report and systematic review. J Neurol. 2021; 268(10): 3517–3548.
    CrossRefPubMed
  16. Asan L, Klebe S, Kleinschnitz C, et al. Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report. Ther Adv Neurol Disord. 2021; 14: 17562864211062824.
    CrossRefPubMed
  17. Saha B, Saha S, Chong WH. 78-year-old woman with opsoclonus myoclonus ataxia syndrome secondary to COVID-19. BMJ Case Rep. 2021; 14(5).
    CrossRefPubMed
  18. Ishaq H, Durrani T, Umar Z, et al. Post-COVID Opsoclonus Myoclonus Syndrome: A Case Report From Pakistan. Front Neurol. 2021; 12: 672524.
    CrossRefPubMed
  19. Ram A, Jeelani H, Kumar D, et al. Generalised myoclonus associated with COVID-19 infection. BMJ Case Rep. 2021; 14(7).
    CrossRefPubMed
  20. El Otmani H, Moutaouakil F, Ouazzani M, et al. Isolated generalized myoclonus immune-mediated by SARS-CoV-2: an illustrative videotaped case. Neurol Sci. 2021; 42(8): 3411–3413.
    CrossRefPubMed
  21. Werner J, Reichen I, Huber M, et al. Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report. BMC Infect Dis. 2021; 21(1): 298.
    CrossRefPubMed
  22. Emekli AS, Parlak A, Göcen NY, et al. Anti-GAD associated post-infectious cerebellitis after COVID-19 infection. Neurol Sci. 2021; 42(10): 3995–4002.
    CrossRefPubMed
  23. Przytuła F, Błądek S, Sławek J. Two COVID-19-related video-accompanied cases of severe ataxia-myoclonus syndrome. Neurol Neurochir Pol. 2021; 55(3): 310–313.
    CrossRefPubMed
  24. Shetty K, Jadhav AM, Jayanthakumar R, et al. Myoclonus-Ataxia Syndrome Associated with COVID-19. J Mov Disord. 2021; 14(2): 153–156.
    CrossRefPubMed
  25. Giannantoni NM, Rigamonti E, Rampolli FI, et al. Myoclonus and Cerebellar Ataxia Associated with SARS-CoV-2 Infection: Case Report and Review of the Literature. Eur J Case Rep Intern Med. 2021; 8(5): 002531.
    CrossRefPubMed
  26. Sundar US, Shah MH, Merchant SA, et al. Acute Ataxia and Myoclonus in COVID-19: A Case Series. Ann Indian Acad Neurol. 2021; 24(5): 807–809.
    CrossRefPubMed
  27. Emamikhah M, Babadi M, Mehrabani M, et al. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. J Neurovirol. 2021; 27(1): 26–34.
    CrossRefPubMed
  28. Foucard C, San-Galli A, Tarrano C, et al. Acute cerebellar ataxia and myoclonus with or without opsoclonus: a para-infectious syndrome associated with COVID-19. Eur J Neurol. 2021; 28(10): 3533–3536.
    CrossRefPubMed
  29. Smyth D, Kyaw KM, Legister A, et al. Post-COVID-19 opsoclonus-myoclonus syndrome and encephalopathy associated with leucine-rich glioma-inactivated 1 (LGI-1) antibodies. J Neurol Sci. 2021; 430: 119982.
    CrossRefPubMed
  30. Guerra AF, Martinelli I, Rispoli V, et al. Ataxia-Myoclonus Syndrome in Patients with SARS-CoV-2 Infection. Can J Neurol Sci. 2022; 49(6): 824–825.
    CrossRefPubMed
  31. Urrea-Mendoza E, Okafor K, Ravindran S, et al. Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) Associated with SARS-CoV-2 Infection: Post-Infectious Neurological Complication with Benign Prognosis. Tremor Other Hyperkinet Mov (N Y). 2021; 11: 7.
    CrossRefPubMed
  32. Sanguinetti SY, Ramdhani RA. Opsoclonus-Myoclonus-Ataxia Syndrome Related to the Novel Coronavirus (COVID-19). J Neuroophthalmol. 2021; 41(3): e288–e289.
    CrossRefPubMed
  33. Chacko J, Maramattom BV. Para-Infectious Opsoclonus Myoclonus Syndrome with COVID-19. Ann Indian Acad Neurol. 2022; 25(3): 546–548.
    CrossRefPubMed
  34. Fernandes J, Puhlmann P. Opsoclonus myoclonus ataxia syndrome in severe acute respiratory syndrome coronavirus-2. J Neurovirol. 2021; 27(3): 501–503.
    CrossRefPubMed
  35. Vinod V, Younis M, Mubarik H, et al. An Interesting Case of SARS-CoV-2 (COVID-19) Encephalopathy in a 52-Year-Old Male - Case Report. Clinical Case Reports: Open Access. 2021; 4(4).
    CrossRef
  36. S M, M P. PR, S., Jayaraj, K. M., Sakthivelayutham, S., Saravanan, R. V., & Mugundhan, K. . Case Report Generalised Myoclonus and Cerebellar Ataxia Associated with COVID-19: A Case Report. GLIMPSES OF NATCON. 2021; 120(1): 48–9.
  37. Talaei M, Ingram G. Yuletide tremor, twitches and tunes. Journal of Neurology, Neurosurgery & Psychiatry. 2022; 93(6): A99.3–A99.
    CrossRef
  38. Serrazina F, Salavisa M, Sá F, et al. Myoclonic Encephalopathy Related to SARS-CoV-2 Infection. Mov Disord Clin Pract. 2022; 9(4): 540–541.
    CrossRefPubMed
  39. Vijayaraghavan R, Paramanandam V, Sankaranarayanan M, et al. The Double Whammy-Opsoclonus-Myoclonus-Ataxia Syndrome and COVID-19: A Case Report. Ann Indian Acad Neurol. 2022; 25(4): 731–733.
    CrossRefPubMed
  40. Rodriguez-Quiroga S, Aldecoa M, Morera N, et al. Ataxia Myoclonus Syndrome in Mild Acute COVID-19 Infection. Cerebellum. 2022 [Epub ahead of print]: 1–3.
    CrossRefPubMed
  41. Ben Mohamed D, Zouari R, Ketata J, et al. Myoclonus status revealing COVID 19 infection. Seizure. 2023; 104: 12–14.
    CrossRefPubMed
  42. Kato S, Yoshikura N, Kimura A, et al. Possible Autoimmune Encephalitis Associated with the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Successfully Treated with Steroids. Intern Med. 2022; 61(24): 3739–3741.
    CrossRefPubMed
  43. Godani M, Beronio A, Lanza G. Post-COVID-19 Myoclonus-Ataxia Syndrome Responsive to Intravenous Immunoglobulins. Mov Disord Clin Pract. 2022; 9(Suppl 2): S6–S8.
    CrossRefPubMed
  44. Grazzini M, Godani M, Grisanti S, et al. Acute Cerebellar Ataxia and Myoclonus in SARS-CoV-2-Related Encephalopathy Responsive to Immunotherapy: A Case Series. Mov Disord Clin Pract. 2022 [Epub ahead of print].
    CrossRefPubMed
  45. Chattopadhyay S, Sengupta J, Basu S. Post-infectious cerebellar ataxia following COVID-19 in a patient with epilepsy. Clin Exp Neuroimmunol. 2022 [Epub ahead of print].
    CrossRefPubMed
  46. Osawa K, Sugiyama A, Uzawa A, et al. Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19. Intern Med. 2022; 61(7): 1071–1076.
    CrossRefPubMed
  47. Przytuła F, Sławek J. Post–COVID-19 Myoclonus–Ataxia Syndrome – is there really a need for intravenous immunoglobulin treatment in all cases? Mov Disord Clin Pract.
  48. Anand P, Zakaria A, Benameur K, et al. Myoclonus in Patients With Coronavirus Disease 2019: A Multicenter Case Series. Crit Care Med. 2020; 48(11): 1664–1669.
    CrossRefPubMed
  49. Chaumont H, San-Galli A, Martino F, et al. Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection. J Neurol. 2020; 267(11): 3121–3127.
    CrossRefPubMed
  50. Clark JR, Liotta EM, Reish NJ, et al. Abnormal movements in hospitalized COVID-19 patients: A case series. J Neurol Sci. 2021; 423: 117377.
    CrossRefPubMed
  51. Cuhna P, Herlin B, Vassilev K, et al. Movement disorders as a new neurological clinical picture in severe SARS-CoV-2 infection. Eur J Neurol. 2020; 27(12): e88–e90.
    CrossRefPubMed
  52. Grieb A, Seitz T, Kitzberger R, et al. COVID-19-associated myoclonus in a series of five critically ill patients. Wien Klin Wochenschr. 2021; 133(17-18): 902–908.
    CrossRefPubMed
  53. Hewan H, Yang A, Vaddiparti A, et al. Nonepileptic Myoclonus in COVID-19: Case Report. Neurohospitalist. 2022; 12(1): 86–89.
    CrossRefPubMed
  54. Muccioli L, Rondelli F, Ferri L, et al. Subcortical Myoclonus in Coronavirus Disease 2019: Comprehensive Evaluation of a Patient. Mov Disord Clin Pract. 2020; 7(8): 971–973.
    CrossRefPubMed
  55. Ros-Castelló V, Quereda C, López-Sendón J, et al. Post-Hypoxic Myoclonus after COVID-19 Infection Recovery. Mov Disord Clin Pract. 2020; 7(8): 983–984.
    CrossRefPubMed
  56. Franke C, Ferse C, Kreye J, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021; 93: 415–419.
    CrossRefPubMed
  57. Coiffard B, Guedj E, Daumas A, et al. Brain PET metabolic abnormalities in a case of varicella-zoster virus encephalitis. Clin Nucl Med. 2014; 39(9): e389–e391.
    CrossRefPubMed
  58. Choi KD, Kim JS, Park SH, et al. Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry. 2006; 77(4): 525–528.
    CrossRefPubMed
  59. Oguro K, Kobayashi J, Aiba H, et al. Opsoclonus-myoclonus syndrome with abnormal single photon emission computed tomography imaging. Pediatr Neurol. 1997; 16(4): 334–336.
    CrossRefPubMed
  60. Ashrafi F, Salari M, Hojjati Pour F. Chorea as a Post-COVID-19 Complication. Mov Disord Clin Pract. 2022 [Epub ahead of print]; 9(8): 1144–1148.
    CrossRefPubMed
  61. Revert Barberà A, Estragués Gazquez I, Beltrán Mármol MB, et al. Bilateral chorea as a manifestation of cerebral venous sinus thrombosis associated with COVID-19. Neurologia (Engl Ed). 2022; 37(6): 507–509.
    CrossRefPubMed
  62. Sawczyńska K, Wężyk K, Bosak M, et al. Acute-onset chorea and confusional state in 77-year-old COVID-19 patient: a case report. Neurol Neurochir Pol. 2022; 56(1): 106–110.
    CrossRefPubMed
  63. Hassan M, Khan NU, Iqbal M, et al. Neurological complications of SARS-CoV-2: A single-center case series authors. Brain Hemorrhages. 2021; 2(4): 161–164.
    CrossRefPubMed
  64. Cotta Ramusino M, Perini G, Corrao G, et al. Sars-Cov-2 in a Patient with Acute Chorea: Innocent Bystander or Unexpected Actor? Mov Disord Clin Pract. 2021; 8(6): 950–953.
    CrossRefPubMed
  65. Ghosh R, Dubey S, Roy D, et al. Choreo-ballistic movements heralding COVID-19 induced diabetic ketoacidosis. Diabetes Metab Syndr. 2021; 15(3): 913–917.
    CrossRefPubMed
  66. Byrnes S, Bisen M, Syed B, et al. COVID-19 encephalopathy masquerading as substance withdrawal. J Med Virol. 2020; 92(11): 2376–2378.
    CrossRefPubMed
  67. Salari M, Etemadifar M. Two Cousins with Acute Hemichorea after BBIBP-CorV (Sinopharm) COVID-19 Vaccine. Mov Disord. 2022; 37(5): 1101–1103.
    CrossRefPubMed
  68. Matar E, Manser D, Spies JM, et al. Acute Hemichorea-Hemiballismus Following COVID-19 (AZD1222) Vaccination. Mov Disord. 2021; 36(12): 2714–2715.
    CrossRefPubMed
  69. Ryu DW, Lim EY, Cho AH. A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine. Neurol Sci. 2022; 43(2): 771–773.
    CrossRefPubMed
  70. Batot C, Chea M, Zeidan S, et al. Clinical and Radiological Follow-Up of a Pfizer-BioNTech COVID-19 Vaccine-Induced Hemichorea-Hemiballismus. Tremor Other Hyperkinet Mov (N Y). 2022; 12: 16.
    CrossRefPubMed
  71. Talaei M, Ingram G. Yuletide tremor, twitches and tunes. Journal of Neurology, Neurosurgery & Psychiatry. 2022; 93(6): A99.3–A99.
    CrossRef
  72. Henry, M., Fadel, R., Miller MD, J. B., Suleyman, G., Abreu-Lanfranco, O., & Brar, I. COVID-19 Presenting with Neurological Symptoms. Case Reports. 2020; 85.
  73. Klein S, Davis F, Berman A, et al. A Case Report of Coronavirus Disease 2019 Presenting with Tremors and Gait Disturbance. Clin Pract Cases Emerg Med. 2020; 4(3): 324–326.
    CrossRefPubMed
  74. Diezma-Martín AM, Morales-Casado MI, García-Alvarado N, et al. Tremor and ataxia in COVID-19. Neurologia (Engl Ed). 2020; 35(6): 409–410.
    CrossRefPubMed
  75. Passaretti M, De Biase A, Paparella G, et al. Worsening of Essential Tremor After SARS-CoV-2 Infection. Cerebellum. 2023; 22(1): 155–158.
    CrossRefPubMed
  76. Pistoia F, Ornello R, Sucapane P, et al. Symptoms of gait and coordination impairment in a patient with COVID-19 interstitial pneumonia. Neurological Sciences. 2021; 42(8): 3083–3086.
    CrossRef
  77. Piscitelli D, Perin C, Tremolizzo L, et al. Functional movement disorders in a patient with COVID-19. Neurol Sci. 2020; 41(9): 2343–2344.
    CrossRefPubMed
  78. Zariffeh A, Youssef AS, Rizvi F, et al. Post Severe Acute Respiratory Syndrome Coronavirus 2 Infection Tremors in a Nonverbal Autistic Adolescent. Cureus. 2021; 13(7): e16296.
    CrossRefPubMed
  79. John A, Hsieh B, Chandra A, et al. Intention Tremor as an Adverse Effect of Remdesivir Therapy for COVID-19 in an Obstetric Patient. MedDocs Publishers. 2021.
  80. Bhagavan SM, Beladakere Ramaswamy S, Mehta TR, et al. A 62-Year-Old Man Presenting with Bilateral Tremor of the Upper Limb After a Diagnosis of COVID-19 with Confirmed Volumetric Brain Loss. Am J Case Rep. 2022; 23: e934955.
    CrossRefPubMed
  81. Perrin P, Collongues N, Baloglu S, et al. Cytokine release syndrome-associated encephalopathy in patients with COVID-19. Eur J Neurol. 2021; 28(1): 248–258.
    CrossRefPubMed
  82. Pilotto A, Cristillo V, Cotti Piccinelli S, et al. Long-term neurological manifestations of COVID-19: prevalence and predictive factors. Neurol Sci. 2021; 42(12): 4903–4907.
    CrossRefPubMed
  83. Portela-Sánchez S, Sánchez-Soblechero A, Melgarejo Otalora PJ, et al. Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic. Eur J Neurol. 2021; 28(10): 3339–3347.
    CrossRefPubMed
  84. Albu S, Vallès M, Kumru H. Diagnostic challenges of functional neurological disorders after covid-19 disease or vaccination: case series and review of the literature. Acta Neurol Belg. 2022 [Epub ahead of print]: 1–12.
    CrossRefPubMed
  85. de Souza A, Jacques R, Mohan S. Vaccine-Induced Functional Neurological Disorders in the Covid-19 Era. Can J Neurol Sci. 2022 [Epub ahead of print]: 1–5.
    CrossRefPubMed
  86. Schneider SA, Hennig A, Martino D. Relationship between COVID-19 and movement disorders: A narrative review. Eur J Neurol. 2022; 29(4): 1243–1253.
    CrossRefPubMed
  87. Piano C, Bove F, Tufo T, et al. Lazio DBS Study Group. Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey. Front Neurol. 2020; 11: 616550.
    CrossRefPubMed
  88. Przytuła F, Dulski J, Sobstyl M, et al. Battery for deep brain stimulation depletion in Parkinson's Disease and dystonia patients - a systematic review. Neurol Neurochir Pol. 2021; 55(4): 346–350.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl